NFE2L2 and diabetes mellitus: Other studies also revealed that another Nrf2 activator, sulforaphane, as well as the HO-1 inducer, CoPP, both inhibited neuropathic pain provoked by CCI or associated with diabetes [24,25,41,42] and inflammatory pain caused by CFA injection [27].